Tenor H - Search Results

1

Phosphodiesterase inhibitors: history of pharmacology.

Schudt C, Hatzelmann A, Beume R, Tenor H. Schudt C, et al. Among authors: tenor h. Handb Exp Pharmacol. 2011;(204):1-46. doi: 10.1007/978-3-642-17969-3_1. Handb Exp Pharmacol. 2011. PMID: 21695634 Review.

2

Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.

Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A. Tenor H, et al. Br J Pharmacol. 2002 Feb;135(3):609-18. doi: 10.1038/sj.bjp.0704480. Br J Pharmacol. 2002. PMID: 11834608 Free PMC article.

3

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. Hatzelmann A, et al. Among authors: tenor h. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Pulm Pharmacol Ther. 2010. PMID: 20381629 Review.

4

Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.

Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K, Bethke TD. Tenor H, et al. Handb Exp Pharmacol. 2011;(204):85-119. doi: 10.1007/978-3-642-17969-3_3. Handb Exp Pharmacol. 2011. PMID: 21695636 Review.

5

Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition.

Selige J, Tenor H, Hatzelmann A, Dunkern T. Selige J, et al. Among authors: tenor h. J Cell Physiol. 2010 May;223(2):317-26. doi: 10.1002/jcp.22037. J Cell Physiol. 2010. PMID: 20082309

6

Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.

Wohlsen A, Hirrle A, Tenor H, Marx D, Beume R. Wohlsen A, et al. Among authors: tenor h. Eur J Pharmacol. 2010 Jun 10;635(1-3):177-83. doi: 10.1016/j.ejphar.2010.03.005. Epub 2010 Mar 19. Eur J Pharmacol. 2010. PMID: 20303939

7

Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S. Izikki M, et al. Among authors: tenor h. J Pharmacol Exp Ther. 2009 Jul;330(1):54-62. doi: 10.1124/jpet.108.148742. Epub 2009 Apr 22. J Pharmacol Exp Ther. 2009. PMID: 19386793

8

Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.

Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, Hatzelmann A, Tenor H, Schudt C, Krüll M, Schütte H, Hippenstiel S, Suttorp N. Seybold J, et al. Among authors: tenor h. Blood. 2005 May 1;105(9):3569-76. doi: 10.1182/blood-2004-07-2729. Epub 2005 Jan 13. Blood. 2005. PMID: 15650061 Free article.

9

Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2.

Diebold I, Djordjevic T, Petry A, Hatzelmann A, Tenor H, Hess J, Görlach A. Diebold I, et al. Among authors: tenor h. Circ Res. 2009 May 22;104(10):1169-77. doi: 10.1161/CIRCRESAHA.109.196592. Epub 2009 Apr 23. Circ Res. 2009. PMID: 19390057

10

Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.

Victoni T, Gicquel T, Bodin A, Daude M, Tenor H, Valença S, Devillier P, Porto LC, Lagente V, Boichot E. Victoni T, et al. Among authors: tenor h. Int Immunopharmacol. 2016 Jan;30:1-8. doi: 10.1016/j.intimp.2015.11.019. Epub 2015 Nov 21. Int Immunopharmacol. 2016. PMID: 26610096 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters